Back to search

PES2020-Prosj.etabl.støtte H2020

Development of the first of its kind medication for combined treatment of viral and bacterial conjunctivitis.

Awarded: NOK 99,999

Pharma Holdings ( is developing eyedrops for the treatment of conjunctivitis caused by both bacteria and viruses based on LTX-109. LTX-109 is a novel antimicrobial synthetic peptide with a fast-acting membrane lysing mode of action. It is a short cationic synthetic peptide (peptidomimetic) which binds preferentially to negatively charged membrane components on microorganisms via electrostatic interactions, subsequently inducing their lysis and death . Pharma Holdings owns a patent family for LTX-109 and its use as a pharmaceutical drug (currently, EU Patent Office: EP2235041; Australia: 2008339611; USA: US8,598,114; Canada: 2,709,884; China: ZL200880126952.0; Japan: US8,598,114). The clinicians have considerable difficulty in making a correct clinical distinction between bacterial and viral conjunctivitis. Currently, there is no medication targeting both bacterial and viral conjunctivitis – making our “all in one” innovative approach demanded by the market. Further, resistance against the current available treatment options is on the increase prompting pharmaceutical companies to develop new efficacious drugs with low propensity toward resistance development. Further, the pathogen causing viral conjunctivitis is most often Adenovirus, for which there is no medication available and our innovative treatment may become the first on the market for this condition. Conjunctivitis Drugs Market is expected to register 3.1% CAGR during the forecast period of 2019 to 2025 and will be valued at USD 1.18 Billion in 2025.

Funding scheme:

PES2020-Prosj.etabl.støtte H2020